Good morning, everyone. Nice to see you again. Another shiny day here on the Pharmalot corporate campus, where we are recovering from the latest installment in our 'Let's See Them Before They Die' concert series. Accordingly, we are brewing multiple cups of stimulation. Meanwhile, here are a few items to help you get started yourselves. Hope your day goes well and catch you later...
Sanofi-Aventis To Cut More Costs, Sales Force (Bloomberg News)
Abbott And Neurocrine Sign Deal For Endometriosis Drug (Reuters)
Cipla Signs Chinese Partner To Make Biosimilars (Bloomberg News)
Sanofi-Aventis Buys Canderm Pharma (Montreal Gazette)
The New World Order In R&D (InPharm)
USDA Approves Vaccine For Dog Flu (Los Angeles Times)
Amylin Stock Hit On Bydureon Data (Reuters)
Pfizer Creates Orphan Disease Research Division (PharmaTimes)
Coffee pix thx to chichcacha flickr creative commons
3 Comments
On the R&D New Wordl Order -- Reuters is running a similar, but less detailed "Special Report" -- on the 21st Century big pharma stalled R&D maching, in pharma this morning.
Namaste, and great stuff, Ed!
Wow -- I'm going back to Starbuck's, to get MORE coffee! -- "World" and "machine". My bad(s), above.
Yikes.
"New World Order" terminology is too scary. I much prefer that we drill down on the new paradigm shift towards more venture-centric activities.